Endocrinology, Diabetes News | Endocrine Treatment & Research
A free diabetes, endocrinology and medical news article resource for endocrinologists and physicians. Endocrinology conference coverage and drug information.
How Do GLP-1 Receptor Agonists, Like Ozempic or Mounjaro, Work?
Jun 14, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Glucagon-like peptide-1 (GLP-1) is a hormone released when food is eaten to slow gastric emptying, the process by which food leaves the stomach, so that the body can absorb nutrients from food.
Type 2 Diabetes Medications That Induce Weight Loss
Mar 22, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. A predominant risk factor for type 2 diabetes is being overweight or obese, so weight loss goals while maintaining normal blood sugar levels are very important for some patients.
GLP-1 Agonists - Endocrinology Advisor
Oct 8, 2024 · Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are a newer class of medications that are US Food and Drug Administration (FDA)-approved to manage type 2 diabetes and obesity in conjunction with diet and lifestyle changes. 1 GLP-1 agonists affect glycemic control and body weight by increasing insulin production and release in a glucose-dependent manner; decreasing glucagon secretion ...
Promising Obesity Pharmacotherapies on the Horizon
Oct 25, 2024 · According to new population data from the Centers for Disease Control and Prevention (CDC), the prevalence of obesity continues to remain high in the US, making the demand for effective treatments even more urgent. The recent success of drug therapies such as semaglutide and tirzepatide has fueled the research into this chronic condition, bringing new hope to patients who continue to struggle ...
Diabetic Ketoacidosis (DKA) - Endocrinology Advisor
Apr 2, 2024 · Diabetic ketoacidosis (DKA) is an acute complication of diabetes that results from absolute or relative insulin deficiency. 1,2 It is characterized by the presence of metabolic acidosis, ketonemia, and hyperglycemia. 2 With prompt treatment, most patients with DKA recover, but in rare cases, such as patients who develop cerebral edema or have an underlying illness, DKA can become life ...
Type 2 Diabetes Mellitus - Endocrinology Advisor
Type 2 diabetes mellitus is a metabolic disorder characterized by dysregulation of blood glucose caused by relative insulin deficiency and insulin resistance. 1 It is a progressive condition that have serious adverse effects on multiple organs and body functions, but it can be successfully managed with treatment that usually includes lifestyle …
Improvements in Insulin Resistance With Semaglutide Primarily a …
Apr 16, 2019 · Treatment with semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) analog, consistently reduced body weight and insulin resistance in patients with type 2 diabetes, with improvements in insulin resistance being positively associated with weight loss, according to study results published in The Journal of Clinical Endocrinology & Metabolism. ...
The 2023 Update to the American Diabetes Association’s …
Jan 27, 2023 · Note: The 2024 American Diabetes Association guideline summary is available here.. The American Diabetes Association (ADA) just published their yearly updated guidelines for the “Standards of Care in Diabetes” in Diabetes Care.. As new research and treatment options for patients with diabetes emerge, the standard of care for these patients continues to evolve.
Diabetes Progression Reduced Via Semaglutide Among Adults …
Jul 17, 2024 · Long-term semaglutide use reduces progression to type 2 diabetes and increases regression to normoglycemia among individuals with cardiovascular disease (CVD) and overweight/obesity without diabetes, according to findings published in Diabetes Care.. Weight loss is associated with improved insulin sensitivity and may reduce risk for …